Adherence to Aromatase Inhibitors: The Role of Partners

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02753985

Enrollment

Registered

2016-04-28

Start date

2014-07-31

Completion date

2016-04-22

Last updated

2019-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Survivors

Brief summary

This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. Both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. The target number of subjects is 64 (32 patients and 32 partners). The primary method of data collection will be face-to-face semi-structured interviews. These interviews will be audio-recorded.

Interventions

OTHERSurvey

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Women and partners of women with stage I-III breast cancer who 1. have completed primary cancer treatments (surgery, chemotherapy, radiotherapy) 2. have experienced AI side effects 3. live with a romantic partner.

Design outcomes

Primary

Measure	Time frame
Number of Surveys Completed	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026